LAVA Therapeutics NV: restructuring charge — LAVA Therapeutics cuts workforce ~30%, starts strategic review with advisor

LAVA Therapeutics NV

Workforce reduction of approx. 30%; expects $0.5M one-time costs, mostly Q1 2025.
Board initiated strategic review to evaluate sale, merger, licensing, or other options.
Cash, cash equivalents & investments $76.6M as of Dec 31, 2024 (unaudited).
Will continue Phase 1 LAVA-1266 trial in AML/MDS and support Pfizer, J&J partnerships.

item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

LAVA Therapeutics NV announced a restructuring with charges of approximately $0.5 million (approximately 30%).

Type: restructuring
Charge: approximately $0.5 million
Headcount: approximately 30%

Exact text from the filing

On February 20, 2025, LAVA Therapeutics N.V. (the “Company”) adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company is planning a workforce reduction of approximately 30%. The Company anticipates that the reduction in workforce will be completed by July 31, 2025. The Company estimates that it will incur approximately $0.5 million of one-time termination benefits and related taxes related to the workforce reduction, with the majority of such costs to be incurred in the first quarter of 2025.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001104659-25-016712

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.